Filing Flows › Myriad Genetics (MYGN) › Who owns the stock
Who owns Myriad Genetics (MYGN) stock
190 funds reported Myriad Genetics (MYGN) shares in their latest 13F filings, worth $568M in all. The largest holder is BlackRock ($62.2M). Last quarter 113 funds added to their stakes and 91 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 10,890,440 | $62.2M | increase | 2026-06-30 |
| Vanguard Group | 8,225,371 | $50.6M | increase | 2025-12-31 |
| Millennium Management LLC | 6,620,372 | $37.8M | decrease | 2026-06-30 |
| Vestal Point Capital, LP | 5,735,000 | $32.7M | increase | 2026-06-30 |
| State Street | 4,985,060 | $28.5M | increase | 2026-06-30 |
| D. E. Shaw | 4,582,083 | $26.2M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 4,081,376 | $23.3M | increase | 2026-06-30 |
| Acadian Asset Management LLC | 3,126,973 | $17.8M | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 3,079,670 | $17.6M | increase | 2026-06-30 |
| AQR Capital Management LLC | 2,766,689 | $15.8M | increase | 2026-06-30 |
| Morgan Stanley | 2,481,104 | $14.2M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 2,416,197 | $13.8M | increase | 2026-06-30 |
| Goldman Sachs Group | 2,056,843 | $11.7M | decrease | 2026-06-30 |
| Jacobs Levy Equity Management | 1,891,527 | $10.8M | decrease | 2026-06-30 |
| Mackenzie Financial | 2,499,354 | $10.8M | increase | 2026-09-30 |
Myriad Genetics' latest quarter
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most MYGN stock?
By the latest 13F filings: BlackRock ($62.2M); Vanguard Group ($50.6M); Millennium Management LLC ($37.8M); Vestal Point Capital, LP ($32.7M); State Street ($28.5M).
What is the short interest in MYGN?
9,267,385 shares were sold short at the 2026-10-15 settlement, 8.44% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.